Abiopharma

CNS PHARMACEUTICALS, INC. (CNSP) Announces Regulatory Update CNS PHARMACEUTICALS, INC. (CNSP) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • Applications: NDA (New Drug Application) • Regulatory Agencies: FDA (U.S. Food and Drug Administration) • Status: Rejected • Committee Actions: Advisory Committee Meeting Clinical Development:

• targeting high - value preclinical / clinical - stage programs Rapidly Executing a New Corporate Strategy Refocused the company into high - unmet - need neurology/oncology markets with strong commercial viability Purpose - Built Executive Team Highly experienced executive team with deep expertise in neurology, oncology and rare disease drug development and public company transformation x Focused on established markets with clear regulatory pathways and limited treatment options x Legacy programs being positioned for out - licensing to unlock potential non - dilutive upside Rare opportunity for public investors to participate in a venture - style strategic pivot x Lean operating structure designed for capital - efficient development x Targeting assets with strong biological rationale, differentiated profiles and near - term catalysts Focused on Value Generation Targeting novel, differentiated assets addressing indications with high unmet needs, efficient development pathways and clear milestones 5 a Rapid Execution with Key Building Blocks in Place Accomplished executive team with specific & relevant experience Strategic pivot to be built around innovative assets Targeting high - value indications with unmet needs CNS’s New Focus Committed to data - driven, capital efficient value creation Asset Development Asset Acquisition Asset Evaluation March January Rami Levin appointed CEO Pipeline analysis commenced CFO, CTO, CMO & CBO appointed New corporate strategy announced Positive Market Reaction to Recent Strategic Pivots 6 Purpose - Built Executive Team Rami Levin, MBA President & CEO 30 years of global leadership experience across oncology, CNS, rare diseases, endocrinology, and cell and gene therapy, with a proven track record of scaling organizations, advancing late - stage clinical programs, and driving transformative value creation. Eric Faulkner, MSc, MBA Chief Technology Officer Over 30 years of global biotechnology leadership across technical operations, CMC, product launch and commercialization, with deep experience advancing programs from development through regulatory approval and market launch. Lynne Kelley, MD, FACS Chief Medical Officer Over 20 years of clinical and regulatory leadership experience, guiding late - stage development programs through IND, NDA and PMA submissions, presenting to FDA advisory committees, and securing key regulatory designations across oncology and medical device platforms. Steve O’Loughlin Chief Financial Officer 20 years of corporate finance, capital markets and business development experience in the biopharmaceutical industry, with a proven track record of executing strategic transactions, securing significant non - dilutive partnerships, and supporting public company growth. Dylan Wenke, MBA Chief Business Officer Corporate development executive with deep experience originating and executing high - value licensing and strategic transactions, supporting portfolio expansion and capital formation in emerging biotech companies. 7 Outcome of Comprehensive Strategic Review Independent Analysis Across Clinical, Commercial and Capital Dimensions Underscores Need for a Disciplined Reset Legacy Pipeline Review Strong scientific merit, but GBM focus not aligned with long - term growth strategy Encouraging clinical activity in recurrent GBM supports continued development TPI 287: Advanced through randomized Phase 2 evaluation, generating meaningful data in a historically difficult indication Berubicin: Exploring out - licensing opportunities for legacy assets to advance their development Outcome of Review Defines Strategic Path Forward Executing a disciplined path forward, leveraging newly assembled executive team’s deep expertise across clinical development to identify and advance potential high - value asset Redirect corporate focus toward larger, high - value neurology/oncology markets 8 Focusing on Neurology and Oncology 1. Grand View Research. Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report. Available at: https://www.grandviewresearch.com/industry - analysis/central - nervous - system - cns - therapeutic - market 2. Nova One Advisor. Oncology Drugs Market Size, Share & Trends Analysis Report. Available at:https://www.novaoneadvisor.com/rep ort /oncology - drugs - market Targeting Therapeutic Areas with Proven Investor Interest and Commercial Success, Capitalizing on the Experience of our New Executive Team Neurology Large, growing markets with significant unmet medical need • Global neurological therapeutics market exceeds $138B and continues to expand 1 • Diseases of aging driving increased prevalence of neurodegenerative disease • Advancing biology and regulatory clarity enabling new treatment approaches • Significant commercial portfolio of branded products facing LOE by 2030